Oruka Therapeutics (ORKA) Competitors $26.75 -0.44 (-1.62%) (As of 12:38 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends ORKA vs. VNRX, OCX, ICCC, TRIB, AWH, VRAX, CDIO, BMRA, MYMD, and TNFAShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include VolitionRx (VNRX), OncoCyte (OCX), ImmuCell (ICCC), Trinity Biotech (TRIB), Aspira Women's Health (AWH), Virax Biolabs Group (VRAX), Cardio Diagnostics (CDIO), Biomerica (BMRA), MyMD Pharmaceuticals (MYMD), and TNF Pharmaceuticals (TNFA). These companies are all part of the "diagnostic substances" industry. Oruka Therapeutics vs. VolitionRx OncoCyte ImmuCell Trinity Biotech Aspira Women's Health Virax Biolabs Group Cardio Diagnostics Biomerica MyMD Pharmaceuticals TNF Pharmaceuticals VolitionRx (NYSE:VNRX) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Does the media refer more to VNRX or ORKA? In the previous week, Oruka Therapeutics had 10 more articles in the media than VolitionRx. MarketBeat recorded 12 mentions for Oruka Therapeutics and 2 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.20 beat Oruka Therapeutics' score of 0.03 indicating that VolitionRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VolitionRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in VNRX or ORKA? Oruka Therapeutics received 6 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 100.00% of users gave Oruka Therapeutics an outperform vote while only 11.11% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVolitionRxOutperform Votes411.11%Underperform Votes3288.89% Oruka TherapeuticsOutperform Votes10100.00% Underperform VotesNo Votes Do analysts recommend VNRX or ORKA? VolitionRx presently has a consensus price target of $2.50, indicating a potential upside of 300.51%. Oruka Therapeutics has a consensus price target of $43.17, indicating a potential upside of 61.37%. Given VolitionRx's higher possible upside, analysts plainly believe VolitionRx is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do institutionals & insiders have more ownership in VNRX or ORKA? 8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, VNRX or ORKA? VolitionRx has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Is VNRX or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -3,318.42%. VolitionRx's return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-3,318.42% N/A -165.21% Oruka Therapeutics N/A -20.18%-19.51% Which has preferable earnings and valuation, VNRX or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than VolitionRx. Oruka Therapeutics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$976.52K58.87-$35.32M-$0.40-1.56Oruka TherapeuticsN/AN/A-$5.34M-$6.00-4.46 SummaryOruka Therapeutics beats VolitionRx on 11 of the 18 factors compared between the two stocks. Ad Timothy SykesStop whatever you’re doing!This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.>> Click Here To Sign Up For StocksToTrade’s Algo Alerts << Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.37M$2.56B$5.02B$8.42BDividend YieldN/A0.70%7.49%4.16%P/E Ratio-4.465.94128.4816.64Price / SalesN/A30.591,723.1677.30Price / CashN/A15.5136.9033.53Price / Book0.773.074.595.19Net Income-$5.34M$29.98M$113.94M$223.67M7 Day Performance-11.72%-5.00%110.64%2.76%1 Month Performance5.03%0.62%124.65%8.82%1 Year PerformanceN/A-4.85%155.07%29.33% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics3.7951 of 5 stars$26.75-1.6%$43.17+61.4%N/A$32.37MN/A-4.46N/AUpcoming EarningsNews CoverageVNRXVolitionRx1.8042 of 5 stars$0.61-3.2%$2.50+311.7%-25.0%$55.93M$770,000.00-1.5280Analyst ForecastNews CoverageOCXOncoCyte2.1237 of 5 stars$3.10flat$4.06+31.0%+26.6%$52.17M$1.50M0.00120Analyst ForecastICCCImmuCellN/A$3.59+0.6%N/A-30.8%$28.05M$23.22M-6.7775Upcoming EarningsPositive NewsTRIBTrinity Biotech0.4615 of 5 stars$2.02-8.2%N/A-26.4%$15.39M$56.83M-0.75480Gap DownAWHAspira Women's Health1.1806 of 5 stars$0.93-1.1%$4.40+373.1%-80.9%$14.94M$8.92M-0.64110Upcoming EarningsAnalyst ForecastGap DownVRAXVirax Biolabs Group0.4076 of 5 stars$2.18-1.4%N/A-19.7%$7.04M$160,000.000.005Gap UpCDIOCardio Diagnostics3.0962 of 5 stars$0.26-16.2%$2.00+671.6%-30.6%$5.88M$39,138.000.007Upcoming EarningsHigh Trading VolumeBMRABiomerica0.8981 of 5 stars$0.31flatN/A-56.7%$5.23M$5.51M-0.8660Positive NewsGap DownMYMDMyMD PharmaceuticalsN/A$1.76+4.8%N/A-88.6%$4.17MN/A0.009TNFATNF PharmaceuticalsN/A$1.53-13.1%N/AN/A$3.63MN/A0.006Positive NewsGap Down Related Companies and Tools Related Companies VNRX Competitors OCX Competitors ICCC Competitors TRIB Competitors AWH Competitors VRAX Competitors CDIO Competitors BMRA Competitors MYMD Competitors TNFA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORKA) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
